Thrombotic thrombocytopenic purpura associated with clopidogrel: Further evaluation

Canadian Journal of Cardiology

Volumn 18, Issue 7, 2002, Pages 771-773

  Paradiso Hardy, Fran L ^a   Papastergiou, John ^a   Lanctôt, Krista L ^a   Cohen, Eric A ^a  

^a Sunnybrook/Women's Coll Health   (Canada)

Author keywords

Platelet aggregation inhibitors

Indexed keywords

ANTILIPEMIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ANAMNESIS; ARTICLE; BAYES THEOREM; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HUMAN; PROBABILITY; QUANTITATIVE ANALYSIS; RELAPSE; RISK BENEFIT ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS;

BAYES THEOREM; CAUSALITY; HUMANS; PLATELET AGGREGATION INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TICLOPIDINE;

EID: 0036332144     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Thrombotic thrombocytopenic purpura associated with clopidogrel
2. The causality assessment of adverse drug reactions using a Bayesian approach
3. If nothing goes wrong, is everything all right? Interpreting zero numerators
4. Increasing mortality from thrombotic thrombocytopenic purpura in the United States - Analysis of national mortality data, 1968-1991
5. Hematologic dyscrasias associated with ticlopidine therapy: Evidence for causality
6. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
7. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators